EQS-News

Medios acquires Dutch market leader in pharmaceutical compounding services

EQS-News: Medios AG / Key word(s): Mergers & Acquisitions/Expansion Medios acquires Dutch market leader in pharmaceutical compounding services 18.03.2024 / 20:46 CET/CEST The issuer is solely responsible for the content of this announcement. Medios acquires Dutch market leader in pharmaceutical compounding services Important first step in building the leading European Specialty Pharma platform – Mid-term targets to be reached already in 2025 Berlin, March 18, 2024 – Medios, the leading provider of Specialty Pharma Solutions in Germany, today announced the acquisition of Ceban Pharmaceuticals B.V. ("Ceban"). Ceban is a fast-growing leading pharmaceutical compounding platform with operations in the Netherlands, Belgium, and Spain. In 2023, Ceban is expected to realize revenue of c. €160 million and an EBITDA-adjusted of c. €29 million corresponding to a margin of c. 18% in 2023.  The acquisition marks an important step in Medios’ growth strategy aimed at building the leading European Specialty Pharma platform. Highlights:

• Ceban is the Dutch market leader in compounding and has growing market positions in Belgium and Spain.
• The acquisition strongly positions Medios to benefit from the significant growth in homecare, clinics, and hospitals in the Netherlands and Belgium.
• Value creation through diversification, leveraging synergy and cross-selling opportunities.
• Ceban’s internationally experienced management team will stay in the company and further drive growth in existing and new geographies.
• The purchase price for 100% of Ceban shares includes a cash component of €235.3 million and 1.7 million Medios shares.
• Medios preliminary figures for 2023: Group revenue increased by c. 11.0% to around €1.8 billion; EBITDA pre¹ increased by 10.3% to around € 60.5 million with an accordingly stable EBITDA pre¹ margin of 3.4%.
• Assuming the completion of the acquisition of Ceban in the second quarter of 2024 Medios expects a substantial increase in revenue and margin for FY 2024: revenue in a range of €1.9 to €2.1 billion and in a range of EBITDA pre from €82 to €91 million, which reflects a margin of around 4.3% based on the mean value of the respective revenue and EBITDA pre¹ range.
• Mid-term outlook for FY 2025: Revenue of around €2.15 billion and EBITDA pre of approx. €110 million reflecting a margin of 5.1% in FY 2025.

Matthias Gaertner, CEO of Medios: "The acquisition of Ceban is an important milestone for our European expansion strategy. With its market leading position in the Netherlands and growing market positions in Belgium and Spain, Ceban is excellently positioned for further growth and highly profitable. Through our established Specialty Pharma platform in Germany, we are also creating cross-selling opportunities and synergies in procurement. Moreover, the portfolio of Ceban offers a strategic diversification of our activities, while tapping into attractive growth markets. All in all, this is a truly transformative transaction for Medios. I am extremely proud that we once again can deliver on our promises and expect to deliver on our ambitious mid-term targets already in 2025.”